On April 22, 2024 Celularity Inc. (NASDAQ: CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, reported that it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day (Press release, Celularity, APR 22, 2024, View Source [SID1234642191]). The Investor and R&D Day, scheduled for Tuesday, May 21, 2024, from 12:00 p.m. to 4:00 p.m. ET in Florham Park, NJ, will showcase progress and advancements of Celularity’s placental technology platform and clinical development pipeline and future growth expectations for its commercial advanced biomaterials business. The event will feature members of Celularity’s executive management team, including:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Celularity Executive Management:
Robert J. Hariri, M.D., Ph.D., – Celularity Chairman, CEO and Founder
Stephen Brigido, DPM – President, Degenerative Diseases
Adrian Kilcoyne M.D., M.P.H., M.B.A.- Chief Medical Officer
Ramji Krishnan, Ph.D.-Chief Technology Officer
A live webcast of the Investor and Analyst R&D Day can be accessed by visiting the Investor Relations section of Celularity’s website at www.celularity.com. A replay will also be available for 30 days following the event. An invited panel of expert medical speakers will provide insights into the technology and programs as well.
"We are very excited to host our first on-site and virtual Investor and Analyst R&D Day at our world-class headquarters, research, and manufacturing center. We will showcase the capabilities resident at Celularity and share the progress made in our development programs and commercial business. Our unique bifurcated regenerative and cellular medicine business model, which leverages both clinical and commercial stage technologies, will be presented and toured during the day," added Celularity CEO and Founder. Dr. Robert J. Hariri.